FI106802B - Olennaisesti puhdas ihmisen lisäkilpirauhashormoni - Google Patents
Olennaisesti puhdas ihmisen lisäkilpirauhashormoni Download PDFInfo
- Publication number
- FI106802B FI106802B FI922356A FI922356A FI106802B FI 106802 B FI106802 B FI 106802B FI 922356 A FI922356 A FI 922356A FI 922356 A FI922356 A FI 922356A FI 106802 B FI106802 B FI 106802B
- Authority
- FI
- Finland
- Prior art keywords
- pth
- parathyroid hormone
- human parathyroid
- preparation
- substantially pure
- Prior art date
Links
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 title claims abstract description 66
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 title claims abstract description 66
- 102000058004 human PTH Human genes 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 238000005251 capillar electrophoresis Methods 0.000 claims abstract description 28
- 238000004458 analytical method Methods 0.000 claims abstract description 17
- 239000000356 contaminant Substances 0.000 claims abstract description 17
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 90
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 241000588724 Escherichia coli Species 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 13
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 125000002091 cationic group Chemical group 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 102000030621 adenylate cyclase Human genes 0.000 claims description 4
- 108060000200 adenylate cyclase Proteins 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims 2
- 239000000199 parathyroid hormone Substances 0.000 claims 2
- 229960001319 parathyroid hormone Drugs 0.000 claims 2
- 235000015895 biscuits Nutrition 0.000 claims 1
- -1 cationic ion Chemical class 0.000 claims 1
- 238000011210 chromatographic step Methods 0.000 claims 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 88
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 33
- 238000004007 reversed phase HPLC Methods 0.000 description 31
- 239000002904 solvent Substances 0.000 description 23
- YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229920002684 Sepharose Polymers 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000005194 fractionation Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008135 aqueous vehicle Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- JSMYHXFFKXKZRN-SBMIAAHKSA-N (2s,3s,4s)-3-(carboxymethyl)-4-(2-hydroxyphenyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C[C@@H]1[C@@H](C(O)=O)NC[C@@H]1C1=CC=CC=C1O JSMYHXFFKXKZRN-SBMIAAHKSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 108091005598 amidated proteins Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 101150042295 arfA gene Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010884 ion-beam technique Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 101150087557 omcB gene Proteins 0.000 description 1
- 101150115693 ompA gene Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Pyrane Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70711491 | 1991-05-23 | ||
| US07/707,114 US5208041A (en) | 1991-05-23 | 1991-05-23 | Essentially pure human parathyroid hormone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI922356A0 FI922356A0 (fi) | 1992-05-22 |
| FI922356A FI922356A (fi) | 1992-11-24 |
| FI106802B true FI106802B (fi) | 2001-04-12 |
Family
ID=24840399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI922356A FI106802B (fi) | 1991-05-23 | 1992-05-22 | Olennaisesti puhdas ihmisen lisäkilpirauhashormoni |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5208041A (no) |
| EP (1) | EP0515228B1 (no) |
| JP (1) | JP2563726B2 (no) |
| KR (1) | KR970007755B1 (no) |
| AT (1) | ATE164394T1 (no) |
| CA (1) | CA2068438C (no) |
| DE (1) | DE69224858T2 (no) |
| DK (1) | DK0515228T3 (no) |
| ES (1) | ES2115642T3 (no) |
| FI (1) | FI106802B (no) |
| HK (1) | HK1004340A1 (no) |
| IE (1) | IE921672A1 (no) |
| IL (3) | IL101829A (no) |
| NO (2) | NO304190B1 (no) |
| NZ (1) | NZ242855A (no) |
| ZA (1) | ZA923735B (no) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420242A (en) * | 1986-10-22 | 1995-05-30 | Kaare M. Gautvik | Production of human parathyroid hormone from microorganisms |
| USRE37919E1 (en) | 1989-05-12 | 2002-12-03 | The General Hospital Corporation | Recombinant DNA method for production of parathyroid hormone |
| TW273513B (no) * | 1993-10-27 | 1996-04-01 | Chugai Pharmaceutical Co Ltd | |
| US20020193338A1 (en) * | 1994-02-18 | 2002-12-19 | Goldstein Steven A. | In vivo gene transfer methods for wound healing |
| US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
| US6074840A (en) | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
| US5763416A (en) | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
| US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| AU745122B2 (en) | 1997-07-30 | 2002-03-14 | Emory University | Novel bone mineralization proteins, DNA, vectors, expression systems |
| US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| DZ2873A1 (fr) | 1998-08-19 | 2003-12-15 | Lilly Co Eli | Procédé pour augmenter la dureté et la rigidité osseuse. |
| US6495662B1 (en) * | 1998-10-22 | 2002-12-17 | The General Hospital Corporation | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
| AU4217299A (en) * | 1998-11-30 | 2000-06-19 | General Hospital Corporation, The | Pth1r and pth3r receptors, methods and uses thereof |
| US7820393B2 (en) * | 1999-01-14 | 2010-10-26 | Scantibodies Laboratory, Inc. | Methods, kits and antibodies for detecting parathyroid hormone |
| US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| WO2004028444A2 (en) * | 1999-06-02 | 2004-04-08 | Scantibodies Laboratory, Inc. | Parathyroid hormone antagonists and uses thereof |
| US20080108086A1 (en) * | 1999-06-02 | 2008-05-08 | Cantor Thomas L | Parathyroid hormone antagonists and uses thereof |
| AU7734800A (en) * | 1999-09-29 | 2001-04-30 | General Hospital Corporation, The | Polypeptide derivatives of parathyroid hormone (pth) |
| MY136546A (en) * | 2000-06-30 | 2008-10-31 | Asubio Pharma Co Ltd | A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component |
| US6387711B1 (en) * | 2000-08-11 | 2002-05-14 | Quest Diagnostics Investments Incorporated | Liquid intact parathyroid hormone (PTH) standards |
| US6905886B2 (en) * | 2000-08-11 | 2005-06-14 | Quest Diagnostics Investments Incorporated | Preservative solutions |
| JP4837888B2 (ja) * | 2001-07-23 | 2011-12-14 | ザ ジェネラル ホスピタル コーポレイション | コンホメーションが拘束された副甲状腺ホルモン（ｐｔｈ）類似体 |
| US20040067526A1 (en) * | 2002-10-03 | 2004-04-08 | Cantor Thomas L. | Methods for diagnosing and guiding treatment of bone turnover disease |
| EP1610813A4 (en) * | 2003-03-19 | 2009-07-01 | Gen Hospital Corp | PARATHYROIDAL HORMONES CONFORMALLY CONFORMALLY CONSTRAINED WITH PROPELLER STABILIZERS $ G (A) |
| KR100540659B1 (ko) * | 2003-07-02 | 2006-01-10 | 삼성전자주식회사 | 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체 |
| WO2005009358A2 (en) | 2003-07-17 | 2005-02-03 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| BRPI0509788A (pt) | 2004-05-13 | 2007-10-23 | Alza Corp | aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides |
| US7541140B2 (en) * | 2004-06-03 | 2009-06-02 | Scantibodies Laboratory, Inc. | Assessing risk for kidney stones using parathyroid hormone agonist and antagonist |
| AU2006315132A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| EP2054077A4 (en) * | 2006-08-04 | 2010-10-13 | Gen Hospital Corp | POLYPEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) |
| AU2008282805B2 (en) * | 2007-08-01 | 2014-05-01 | Chugai Pharmaceutical Co., Ltd. | Screening methods using G-protein coupled receptors and related compositions |
| US8298789B2 (en) * | 2007-08-09 | 2012-10-30 | Usv Limited | Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34) |
| CN102471368A (zh) * | 2009-08-11 | 2012-05-23 | 拜康有限公司 | 色谱方法及其纯化的化合物 |
| EP2509996A1 (en) | 2009-12-07 | 2012-10-17 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| BR112012028949B1 (pt) | 2010-05-13 | 2020-11-17 | Chugai Seiyaku Kabushiki Kaisha | polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica |
| CN108195965B (zh) * | 2011-06-07 | 2021-02-23 | 旭化成制药株式会社 | 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法 |
| CN102993293B (zh) * | 2012-12-05 | 2014-05-07 | 深圳翰宇药业股份有限公司 | 一种特立帕肽醋酸盐的纯化方法 |
| LU100168B1 (en) | 2017-04-12 | 2018-10-15 | Michael Pazianas | Prevention of Bone and Mineral Disorders by Restoring Calcium and Phosphate Homeostasis in Patients Suffering from Chronic Kidney Disease |
| CN115279396A (zh) | 2020-03-30 | 2022-11-01 | 四川泸州步长生物制药有限公司 | 人类甲状旁腺激素(pth)的制剂及用于生产其的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3886132A (en) * | 1972-12-21 | 1975-05-27 | Us Health | Human parathyroid hormone |
| US5223407A (en) * | 1988-08-31 | 1993-06-29 | Allelix Inc. | Excretion of heterologous proteins from e. coli |
| WO1991005050A1 (en) * | 1989-09-29 | 1991-04-18 | Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada | Synthesis of mature human parathyroid hormone |
-
1991
- 1991-05-23 US US07/707,114 patent/US5208041A/en not_active Expired - Lifetime
-
1992
- 1992-05-11 IL IL10182992A patent/IL101829A/en not_active IP Right Cessation
- 1992-05-11 IL IL11984092A patent/IL119840A/xx not_active IP Right Cessation
- 1992-05-12 CA CA002068438A patent/CA2068438C/en not_active Expired - Lifetime
- 1992-05-21 NO NO19922000A patent/NO304190B1/no not_active IP Right Cessation
- 1992-05-21 NZ NZ242855A patent/NZ242855A/xx not_active IP Right Cessation
- 1992-05-22 ES ES92304692T patent/ES2115642T3/es not_active Expired - Lifetime
- 1992-05-22 FI FI922356A patent/FI106802B/fi not_active IP Right Cessation
- 1992-05-22 DK DK92304692T patent/DK0515228T3/da active
- 1992-05-22 DE DE69224858T patent/DE69224858T2/de not_active Expired - Lifetime
- 1992-05-22 JP JP4156100A patent/JP2563726B2/ja not_active Expired - Lifetime
- 1992-05-22 EP EP92304692A patent/EP0515228B1/en not_active Expired - Lifetime
- 1992-05-22 KR KR92008730A patent/KR970007755B1/ko not_active IP Right Cessation
- 1992-05-22 AT AT92304692T patent/ATE164394T1/de active
- 1992-05-22 ZA ZA923735A patent/ZA923735B/xx unknown
- 1992-07-01 IE IE167292A patent/IE921672A1/en not_active IP Right Cessation
-
1996
- 1996-12-16 IL IL11984096A patent/IL119840A0/xx unknown
-
1998
- 1998-04-24 HK HK98103454A patent/HK1004340A1/xx not_active IP Right Cessation
-
2006
- 2006-10-24 NO NO2006013C patent/NO2006013I2/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1604992A (en) | 1993-03-11 |
| JP2563726B2 (ja) | 1996-12-18 |
| IL119840A0 (en) | 1997-03-18 |
| HK1004340A1 (en) | 1998-11-20 |
| ZA923735B (en) | 1993-01-27 |
| NO2006013I2 (no) | 2009-12-07 |
| NO304190B1 (no) | 1998-11-09 |
| US5208041A (en) | 1993-05-04 |
| KR970007755B1 (en) | 1997-05-16 |
| CA2068438A1 (en) | 1992-11-24 |
| AU639856B2 (en) | 1993-08-05 |
| ATE164394T1 (de) | 1998-04-15 |
| NZ242855A (en) | 1994-04-27 |
| CA2068438C (en) | 1996-11-12 |
| NO2006013I1 (no) | 2006-11-06 |
| FI922356A (fi) | 1992-11-24 |
| DE69224858D1 (de) | 1998-04-30 |
| EP0515228A3 (no) | 1994-05-04 |
| ES2115642T3 (es) | 1998-07-01 |
| NO922000L (no) | 1992-11-24 |
| EP0515228A2 (en) | 1992-11-25 |
| DK0515228T3 (da) | 1998-09-28 |
| IL119840A (en) | 2005-08-31 |
| IE921672A1 (en) | 1992-12-02 |
| JPH0687897A (ja) | 1994-03-29 |
| FI922356A0 (fi) | 1992-05-22 |
| EP0515228B1 (en) | 1998-03-25 |
| IL101829A0 (en) | 1992-12-30 |
| NO922000D0 (no) | 1992-05-21 |
| DE69224858T2 (de) | 1998-07-23 |
| IL101829A (en) | 1999-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI106802B (fi) | Olennaisesti puhdas ihmisen lisäkilpirauhashormoni | |
| Bennett et al. | Purification of the two major forms of rat pituitary corticotropin using only reversed-phase liquid chromatography | |
| Burtis et al. | Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. | |
| Roberts et al. | Purification and properties of a type. beta. transforming growth factor from bovine kidney | |
| US5013720A (en) | SAP-6-Val proteins and methods | |
| DE69632224T2 (de) | Reduzierung von Gelation von Fettsäureacylierten Proteinen unter Nutzung von Zitratpuffer | |
| Hariharan et al. | Systematic approach to the development of plasma amino acid analysis by high-performance liquid chromatography with ultraviolet detection with precolumn derivatization using phenyl isothiocyanate | |
| JP3285862B2 (ja) | 活性依存性神経栄養因子 | |
| CA1297635C (en) | Protein purification | |
| WO1987006943A1 (en) | Pulmonary hydrophobic surfactant-associated protein of 6,000 daltons molecular weight and multimers thereof | |
| US5290920A (en) | Method of purifying human epidermal growth factor | |
| SANO et al. | AB (type V) and basement membrane (type IV) collagens in the bovine lung parenchyma: electron microscopic localization by the peroxidase-labeled antibody method | |
| Tio et al. | Purification of gonadotropin surge-inhibiting factor from Sertoli cell-enriched culture medium | |
| CA2113868A1 (en) | Ultra-pure human interleukin-6 | |
| FRANCO-BOURLAND et al. | In vivo biosynthesis of L-[35S] Cys-arginine vasopressin,-oxytocin, and-somatostatin: rapid estimation using reversed phase high pressure liquid chromatography | |
| JPH02209896A (ja) | 還元型の非グリコシル化組換ヒトｉｌ↓２、その取得方法、及び薬物としてのその使用 | |
| JPH11508572A (ja) | 等電点電気泳動によるダルバヘプチド抗生物質の精製 | |
| EP0146842B1 (en) | Novel calcitonin and collection thereof | |
| Perry et al. | ε-N-Methyl Lysine: an Additional Amino-acid in Human Plasma | |
| Nicola | [44] Granulocyte colony stimulating factor | |
| IE83494B1 (en) | Essentially pure human parathyroid hormone | |
| Jaffe et al. | HPLC isolation and purification of pheromone biosynthesis activating neuropeptide of Heliothis zea | |
| Rand-Weaver et al. | A rapid procedure for the isolation of bioactive growth hormone | |
| Yamamoto et al. | Identification and purification of apolipoprotein C-III from the serum of cows | |
| Welinder et al. | Binding affinity of monoiodinated insulin tracers isolated after reversed-phase high-performance liquid chromatography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: ALLELIX BIOPHARMACEUTICALS INC. |
|
| PC | Transfer of assignment of patent |
Owner name: NPS PHARMACEUTICALS, INC. Free format text: NPS PHARMACEUTICALS, INC. |
|
| MA | Patent expired |